ArticleThe Lancet regional health. Western Pacific2026
Lifetime health benefits, costs, and cost-effectiveness of salt substitution for stroke survivors in China: a microsimulation modeling study.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Randomized trials have shown that potassium-enriched salt substitutes can lower blood pressure and reduce cardiovascular risk. Although several within-trial cost-effectiveness analyses of these salt substitutes have been reported, the long-term health and economic impacts among Chinese stroke survivors remain unclear. Methods: We adapted the China Cardiovascular Disease Prevention Model to estimate the lifetime health and economic impacts of replacing regular salt with a potassium-enriched salt substitute among Chinese adult stroke survivors from a healthcare sector perspective. Key inputs were drawn from the Salt Substitute and Stroke Study in China (N = 15,249), New Rural Cooperative Medical Scheme, Global Burden of Disease Study, and published literature. Outcomes included quality-adjusted life years (QALYs), direct healthcare costs (2023 USD), and incremental costs per QALY gained, all discounted at 3% annually. We conducted extensive sensitivity analyses to explore the robustness of the findings. Findings: Among 24·1 million Chinese stroke survivors (mean age 64·3 years; 46·5% women), salt substitution was projected to prevent 454,559 recurrent stroke events (a 3·7% reduction) and 482,632 stroke deaths (a 15·0% reduction). The intervention also reduced coronary heart disease events by 72,902 (a 3·8% reduction) and increased life expectancy by 0·74 years over the lifetime horizon. The intervention was estimated to yield 10·79 million additional QALYs (a 5·7% increase) and $417·28 million lower direct healthcare costs (a 0·8% decrease). Results were robust across all sensitivity analyses. Interpretation: Salt substitution was deemed cost-saving-producing better health outcomes at lower costs. Comprehensive adoption of potassium-enriched salt substitutes among Chinese stroke survivors could save lives, improve quality of life, and reduce healthcare costs. Funding: China-NNSF: 72293585; Australia-NHMRC: APP1049417, APP1164206; China-NKRDP: 2023YFC3605000.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.